| 52.95 -0.017 (-0.03%) | 05-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 61.88 | 1-year : | 72.27 |
| Resists | First : | 52.97 | Second : | 61.88 |
| Pivot price | 52.9  |
|||
| Supports | First : | 52.63 | Second : | 52.41 |
| MAs | MA(5) : | 52.95 |
MA(20) : | 52.84 |
| MA(100) : | 44.28 |
MA(250) : | 23.74 |
|
| MACD | MACD : | 0.7  |
Signal : | 0.9 |
| %K %D | K(14,3) : | 91.5 |
D(3) : | 91.8 |
| RSI | RSI(14): 73.9 | |||
| 52-week | High : | 53.18 | Low : | 2.65 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ TERN ] has closed below upper band by 31.4%. Bollinger Bands are 97% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 21 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 53.02 - 53.28 | 53.28 - 53.5 |
| Low: | 52.32 - 52.62 | 52.62 - 52.89 |
| Close: | 52.5 - 52.97 | 52.97 - 53.37 |
Terns Pharmaceuticals, Inc. is a biopharmaceutical firm currently in the clinical development phase, dedicated to advancing novel small-molecule treatments. Its primary focus lies in developing both standalone agents and combination therapies to address non-alcoholic steatohepatitis (NASH) and obesity. The company's pipeline includes several key drug candidates: TERN-101, a farnesoid X receptor agonist distinguished by its liver-specific distribution and non-bile acid properties, is presently undergoing Phase IIa clinical trials for NASH. TERN-201, a vascular adhesion protein-1 inhibitor, is in Phase Ib clinical studies, also targeting NASH. Terns is also progressing TERN-501, a thyroid hormone receptor beta agonist engineered for improved liver targeting and metabolic resilience, through Phase I clinical trials for NASH. Furthermore, the company is advancing TERN-601, an oral small-molecule Glucagon-Like Peptide-1 receptor agonist program, intended for the management of NASH and various metabolic conditions, including obesity. Established in 2016, Terns Pharmaceuticals maintains its corporate headquarters in Foster City, California.
Tue, 09 Jun 2026
Merck To Acquire Terns In $6.7B Deal – Signaling Fresh Push In Competitive Cancer Drug Race - Stocktwits
Fri, 05 Jun 2026
Morgan Stanley no longer >5% holder of Terns Pharmaceuticals (TERN) - Stock Titan
Tue, 05 May 2026
Merck completes purchase of Terns Pharmaceuticals Inc. - ROI-NJ
Tue, 05 May 2026
Merck Completes Acquisition of Terns Pharmaceuticals, Inc. - Yahoo Finance
Wed, 25 Mar 2026
Merck to buy Terns Pharmaceuticals in $6.7B deal - statnews.com
Wed, 25 Mar 2026
Merck To Buy Terns, ‘Unprecedented’ Leukemia Drug for $6.7B as Keytruda Cliff Looms - BioSpace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 116 (M) |
| Shares Float | 115 (M) |
| Held by Insiders | 0.2 (%) |
| Held by Institutions | 109.6 (%) |
| Shares Short | 8,060 (K) |
| Shares Short P.Month | 18,190 (K) |
| EPS | -1.03 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 8.96 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -10 % |
| Return on Equity (ttm) | -14.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.96 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -82 (M) |
| Levered Free Cash Flow | -55 (M) |
| PE Ratio | -51.41 |
| PEG Ratio | 0 |
| Price to Book value | 5.9 |
| Price to Sales | 0 |
| Price to Cash Flow | -74.44 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|